Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCV
Phase 3
- Conditions
- Hepatitis C.Chapter I Certain infectious and parasitic diseases,Viral hepatitis (B15-B19)A00-B99
- Registration Number
- IRCT20080901001155N30
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Patients who have not been treated before
Patients who had been treated before, but their illness recurred
Patients who could not take interferon
Exclusion Criteria
Patients who did not use the medication completely
Patients with severe drug side effects
Patients who were reluctant to participate in the plan
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HCV treatment. Timepoint: 12 weeks after the end of treatment. Method of measurement: HCV- RNA PCR.
- Secondary Outcome Measures
Name Time Method Possible side effect. Timepoint: Weeks 0.2, 4, 8, 12 and response to treatment, 24 weeks after the end of drug use (SVR 24. Method of measurement: weeks 2, 12 and 24 weeks after the end of drug use with use of PCR and 4,8 with use of liver enzymes test.